Parkinson's Trial NCT03402919
Identify cognitive decline in Parkinsons
- Trial ID
- NCT03402919
- Official Title
- The Comprehensive Assessment of Neurodegeneration and Dementia Study
- Goal
- Identify cognitive decline in Parkinsons
- Status
- RECRUITING
- Sponsor
- McGill University
- Study Type
- OBSERVATIONAL
- Enrollment
- 1573 participants
- Conditions
- Dementia, Mild Cognitive Impairment (MCI), Subjective Cognitive Impairment, Parkinson's Disease (PD), Lewy Body Disease(LBD), Mixed Dementia, Frontotemporal Dementia (FTD), Alzheimer Disease (AD), Cognitively Unimpaired, Subjective Cognitive Decline (SCD)
Summary For Families
The goal is to map how cognition and brain changes progress across Parkinson's and related conditions, so clinicians can better detect and track mild cognitive impairment and dementia in people with PD. Instead of testing a drug, participants get detailed neuropsychological testing, MRI scans, and reports from a study partner to link symptoms with brain imaging and build a comprehensive profile over time. The study seeks adults 50 to 90 who speak English or French, can travel to the site and bring a study partner, and includes people from cognitively unimpaired to PD with MCI, while excluding those with other major brain diseases, recent symptomatic stroke, ongoing substance abuse, or MRI contraindications.
Locations
- University of Calgary, Calgary, Alberta, Canada
- University of Alberta Hospital, Edmonton, Alberta, Canada
- Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada
- Island Health, Victoria, British Columbia, Canada
- Veteran's Memorial Building, Halifax, Nova Scotia, Canada
- Hamilton General Hospital, Hamilton, Ontario, Canada
- St. Joseph's Health Care London, London, Ontario, Canada
- Gait and Brain Lab, London, Ontario, Canada
- Bruyère Research Institute, Ottawa, Ontario, Canada
- Kawartha Centre, Peterborough, Ontario, Canada
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- University Health Network Memory Clinic, Toronto, Ontario, Canada
- Baycrest Clinical Unit, Toronto, Ontario, Canada
- University of Waterloo, Waterloo, Ontario, Canada
- Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
- Jewish General Hospital/McGill Memory Clinic, Montreal, Quebec, Canada
- Clinique de cognition Institut universitaire de gériatrie de Montréal, Montreal, Quebec, Canada
- Hôpital Enfant-Jésus, Québec, Quebec, Canada
- Centre de recherche sur le vieillissement CIUSSS de l'Estrie-CHUS, Sherbrooke, Quebec, Canada
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to map how cognition and brain changes progress across Parkinson's and related conditions, so clinicians can better detect and track mild cognitive impairment and dementia in people with PD. Instead of testing a drug, participants get detailed neuropsychological testing, MRI scans, and reports from a study partner to link symptoms with brain imaging and build a comprehensive profile over time. The study seeks adults 50 to 90 who speak English or French, can travel to the site and bring a study partner, and includes people from cognitively unimpaired to PD with MCI, while excluding those with other major brain diseases, recent symptomatic stroke, ongoing substance abuse, or MRI contraindications.
- Who can participate?
- Participants must be between 50 Years and 90 Years.
- Where is this trial located?
- This trial is recruiting at 19 locations.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 7 years and 5 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.
- What procedures are involved in this trial?
- Based on the protocol, this trial involves: Lumbar puncture (spinal tap) (invasive); Thinking & memory tests (non-invasive). Confirm the full schedule with the study coordinator.